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Epstein-Barr virus (EBV)-associated post-transplant smooth muscle tumours (PTSMT), are rare complications following
organ/stem cell transplantation. Despite the mainly benign behaviour of PTSMT, alternative therapies are needed for
those patients with progressive tumours. In tumours not approachable by surgery or reduction of immunosuppression,
the angiogenic microenvironment might be a potential target of therapy, an approach that is well utilised in other soft
tissue neoplasms. In a previous study, we evaluated the expression of EBV-related genes and the microRNA profile in
PTSMT, but so far the characteristics of angiogenesis in PTSMT are not known. Therefore, the aim of this study was to
evaluate the expression pattern of angiogenesis-related genes in PTSMT, in order to identify potential target molecules
for anti-angiogenic therapy.
PTSMT (n = 5 tumours) were compared with uterine leiomyomas (n = 7). Analyses included real-time PCR of 45
angiogenesis-associated genes, immunohistochemistry (CD31, prostaglandin endoperoxide synthase 1/PTGS1) and
assessment of tumour vascularisation by conventional histopathology.
PTSMT showed similar or fewer vessels than leiomyomas. Of the genes under investigation, 23 were down-deregulated
(pro-angiogenic and some anti-angiogenic factors) and five were up-regulated (e.g. PTGS1 which is expressed at very
low levels in leiomyomas but moderately higher levels in PTSMT).
In summary, no particular target molecule could be identified, because tumour angiogenesis in PTSMT is characterised
by low levels of major pro-angiogenic factors and there is no prominent increase in tumour vascularisation. EBV can
induce angiogenesis via its viral late membrane protein 1 (LMP1) but PTSMT frequently do not express LMP1,
which could be an explanation why, despite EBV infection, PTSMT show no exaggerated tumour angiogenesis.
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Epstein-Barr virus (EBV)-associated post-transplant smooth
muscle tumours (PTSMT) are rare complications following
solid graft and stem cell transplantation [1]. The molecular
pathobiology of this rare neoplastic entity is not fully under-
stood and only few experimental analyses have addressed
this issue [1,2]. Tumour cells are thought to be derived from
aberrant myogenous venous/perivascular wall cells [3]. They
express smooth muscle proteins (actin and desmin), but not
CD117, CD34 or other endothelial marker proteins. Histo-
morphology is characterised by mild atypia, low mitotic rate
and absence of prominent tumour necrosis. All in all,
PTSMT show more histological features of benign leiomyo-
mas rather than leiomyosarcomas [1,2] and our group has* Correspondence: Hussein.Kais@MH-Hannover.de
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reproduction in any medium, provided the orpreviously analysed cell cycle factors, cytokines and gene
promoter methylation in PTSMT and found an activated
phosphoinositide 3-kinase (PI3K)/mammalian target of
rapamycin (mTOR) cell cycle pathway as well as ex-
pression of vascular endothelial growth factor (VEGF)
and Fms-related tyrosine kinase 1 (FLT1/VEGFR1) [1].
In general, in addition to endogenous molecular de-
fects which affect mitosis and apoptosis of the tumour
cells, angiogenesis is a major mechanism which con-
tributes to tumour cell survival by supplying the me-
tabolism of aberrant cell proliferation. Currently, for
PTSMT, surgery and reduced immunosuppression are
the therapy of choice [1]. At this point, there is no
proof that patients benefit from conventional chemo-
therapy or radiation alone [1]. In other soft tissue neo-
plasms, numerous studies have addressed the angiogenic
microenvironment as a potential target of therapy. InLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the original/progenitor tumour cell in these neoplasms is
generally thought to be derived from an aberrant perivas-
cular/venous wall cell. This topic is also important in
PTSMT, as these can manifest in any anatomical localisa-
tion and cerebral tumours are in particular associated with
a poor prognosis [1].
From other tumours, in particular renal cell cancer, we
know that hypoxia-inducible factor 1, alpha subunit (HIF1A)
signalling mediates expression of VEGF, platelet-derived
growth factor (PDGF) and angiopoietin via the PI3K/mTOR
pathway [4,5]. These cytokines activate pro-angiogenic re-
ceptors such as VEGFR and PDGF receptors (PDGFR). For
a variety of neoplasms, e.g. soft tissue sarcomas such
as leiomyosarcomas, it has been shown that a VEGFR/
PDGFR-mediated increase of angiogenesis can be inhib-
ited by anti-angiogenic agents [6-9]. The aim of this
analysis was to evaluate the expression pattern of
angiogenesis-related genes in PTSMT, in order to
identify potential target molecules for anti-angiogenic
therapy, in particular for those patients who suffer
from irresectable or progressive tumours.
Material and methods
Tissue specimens
Five EBV+ PTSMT samples from four patients, including
two tumours from one patient (#4), and seven EBV- be-
nign uterine leiomyomas from solid graft recipients were
analysed. These cases had been characterised earlier
(Additional file 1: Table S1) [1]. Formalin-fixed and
paraffin-embedded (FFPE) samples were retrieved from
the archives of the Institute of Pathology (Hannover
Medical School/MHH, Hanover, Germany). The retro-
spective evaluation has been approved by the local eth-
ics committee (MHH).
Expression analysis of angiogenesis-associated factors
Tissue from FFPE blocks with >90% tumour cells were
cut and processed for further PCR analysis. In blocks
with <90% aberrant neoplastic cells, the PTSMT compart-
ments of the specimens were laser microdissected using a
SmartCutPlus-System (MMI, Glattbrugg, Switzerland), as
previously described [1,10]. Cells were digested in protein-
ase K and RNA was extracted with phenol/chloroform
[1,10]. Synthesis of cDNA from mRNA, subsequent pre-
amplification of cDNA and real-time quantitative PCR of
45 angiogenesis-associated genes and three endogenous
controls with a 7900HT Fast Real-Time PCR system were
performed according to the manufacturers’ instructions
(Applied Biosystems, Carlsbad, CA, USA). Endogenous
controls were polymerase (RNA) II (DNA-directed)
polypeptide A, 220 kDa (POLR2), glucuronidase beta
(GUSB) and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH). Delta CT values were converted into 2
-ΔCTvalues (normalised to a mean of endogenous control
genes). Statistical analysis was performed with Prism 5.0
(GraphPad Software, San Diego, CA, USA) by applying
the non-parametric Kruskal-Wallis test followed by the
Mann-Whitney test for two-group comparison. P values <
0.05 were considered as statistically significant.Immunohistochemistry for evaluation of selected genes
Deparaffinised and rehydrated FFPE tissue sections
(1-2 μm) were stained after autoclave pre-treatment. For
staining of platelet/endothelial cell adhesion molecule 1
(VCAM1/CD31), sections were processed in an auto-
mated staining system (Benchmark ULTRA, Ventana
Medical Systems, Inc., Tucson, AZ, USA). Prostaglandin
endoperoxide synthase 1 (prostaglandin G/H synthase
and cyclooxygenase) (PTGS1) was stained manually
(positive control: FFPE prostate cancer tissue). Mouse
monoclonal antibodies were used. Vascularisation was
quantified by counting CD31+ vessels per 10 high
power fields (HPF) and then correlating them in seri-
ally cut haematoxylin-eosin-stained sections. Statistical
analysis was performed with Prism 5.0 as described
above.Results
Vascularisation of PTSMT
As previously described, PTSMT tumour cells them-
selves were negative for CD31. In the cerebral PTSMT
we could previously demonstrate aneuploidy of the MYC
locus 8q24 by fluorescence in situ hybridisation (FISH) [1].
In this case, endothelial cells showed a normal MYC con-
figuration. Thus, a clonal relation between PTSMT and
endothelial cells could not be proven (Additional file 1:
Figure S1).
PTSMT showed similar or fewer vessels than leiomyo-
mas (mean 301/range 201-518 versus mean 511/range
306-789 CD31+ vessels/10 HPF, p = 0.0480; Figure 1).
Corresponding to the low significance level, there was a
broad overlap in vessel density between these two leio-
myomatous tumour entities. Furthermore, gene expres-
sion analysis of CD31 did not correlate with vessel
density. Higher rather than lower expression levels of
CD31 were detectable in PTSMT (mean 20.10/range
5.26-30.48 in PTSMT versus mean 6.76/range 2.44-11.40
in leiomyomas; p = 0.0303). Sinusoids without smooth
muscle cell wall appeared generally smaller in PTSMT
and more hyalinised but, in comparison to leiomyomas
the quantitative difference was not significant. PTSMT
had significantly fewer arterioles, as defined by vessels
with a smooth muscle wall (mean 1 versus 15 vessels/10
HPF, p = 0.0058). In summary, there was no clear evi-
dence that PTSMT are generally more vascularised than
leiomyomas.
Figure 1 Similar vascularisation of PTSMT and leiomyomas. A) Histological counts of vessels. B) CD31+ vessels in PTSMT (original
magnification x200). C) CD31+ vascularisation in leiomyomas (x200). D) Weak PTGS1 protein expression in PTSMT (x400). E) Very weak protein
expression in a leiomyoma (x400).
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PTSMT
Among 45 angiogenesis-associated mediators under in-
vestigation, 28 were significantly deregulated in PTSMT:
23 were down-deregulated and 5 (including CD31, see
above) were up-regulated (Figure 2, Table 1).
Prominently down-regulated factors included e.g. pro-
angiogenic HIF1A, fibroblast growth factor receptor 1
(FGFR1/FLT2), kinase insert domain receptor (VEGFR2/
KDR) and VEGFA as well as anti-angiogenic serpin peptid-
ase inhibitor, clade E (nexin, plasminogen activator inhibi-
tor type 1), member 1 (SERPINE1), thrombospondin 1
(THBS1) and TIMP metallopeptidase inhibitor 2 (TIMP2).Except for CD31, significant differences of other up-
regulated factors were due to very low expression in
leiomyomas rather than strong expression in PTSMT.
These factors were angiopoietin 2 (ANGPT2), PDGFRA,
PTGS1 and thymidine phosphorylase (TYMP). Because
PTGS1 can be inhibited by widely used non-steroidal
anti-inflammatory drugs, immunohistochemistry was
performed for evaluation if the tumour cells showed a
corresponding protein expression. A weak expression
of PTGS1 proteins in PTSMT and leiomyomatous
smooth muscle spindle cells was detectable (Figure 1).
Weak protein expression corresponded with relatively
low transcript expression levels in both tumour types
Figure 2 Representative summary of up- and down-regulated angiogenesis-associated factors in PTSMT.
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0.03/range 0.00-0.08 in leiomyomas; p = 0.0061).
Discussion
Patients suffering from PTSMT benefit from surgical
tumour resection and/or reduction of immunosuppres-
sion [1]. However, surgical respectability depends on
tumour site and, of note, PTSMT can manifest at any lo-
calisation, including the transplanted organ, in particular
liver grafts [1]. Furthermore, multiple PTSMT, e.g. in
the lung, are not suitable for a surgical approach [11].
Due to the rarity of this tumour entity, prospective eval-
uations of therapeutic strategies will not be applicable in
a considerable number of patients. However, additional
therapy options are mandatory for those patients who
cannot be operated and/or whose transplant organ does
not tolerate reduction of immunosuppression. In indi-
vidual patients, it has been shown that inhibition of
mTOR signal pathways by sirolimus might be of thera-
peutic benefit [12-14]. The rationale for administration
of an mTOR signalling inhibitor was based on the find-
ing that PTSMT and HIV-associated SMT, which share
morphological similarities with PTSMT, express mTOR
[2]. However, sirolimus cannot be administered to all
transplanted patients, e.g. after renal transplantation,
because the drug is potentially nephrotoxic. Another
class of drugs which is widely used for systemic ther-
apy of soft tissue neoplasms/sarcomas are anti-angiogenic
agents, e.g. leiomyosarcoma [8]. Basic analysis of tumour-
associated angiogenesis is important for assessing the
vulnerability of a given tumour type to these drugs.
Prominent proliferation of vessels, high expression levels
of pro-angiogenic and low levels of anti-angiogenic genes
would make it likely that PTSMT patients could benefit
from anti-angiogenic drug therapy. Therefore, we evaluatedthe expression profiles of angiogenesis-related factors in
PTSMT. However, in contrast to this assumption we
found almost the opposite: PTSMT showed similar or
even reduced vascularisation, when compared to sporadic
leiomyomas. Furthermore, we could show that this mor-
phological feature was based on a previously unknown
molecular characteristic of PTSMT, namely expression of
low levels of pro-angiogenic factors and high levels of
anti-angiogenic genes. In particular major factors of
hypoxia-inducible angiogenesis such as HIF1A, VEGFA,
VEGFC, VEGFR1/FLT1, VEGFR2/KDR and FGFR1/FLT2
were expressed at low levels. In contrast to PTSMT, leio-
myosarcomas show generally higher expression of VEGFA
than leiomyomas [15-17]. In leiomyosarcoma-derived cell
lines it could be demonstrated that hepatocyte growth fac-
tor (HGF) induces a decrease in anti-angiogeneic THBS1
and an increase in VEGFA [18]. In PTSMT, HGF, THBS1
and VEGFA are all expressed at low levels, indicating
that HGF signalling does not contribute significantly
to tumour angiogenesis. In PTSMT, low levels were
also detectable for other pro-angiogenic genes which
are involved in differentiation and proliferation of endo-
thelial cells, e.g. vascular development-related EPH recep-
tor B4 (EPHB4) and sphingosine-1-phosphate receptor 1
(S1PR1), the endothelium-specific receptor tyrosine kinase
TEK and the growth factor midkine (MDK). Immune
response-associated caveolae are plasma membrane invag-
inations of 60-80 nm in diameter in endothelial cells,
smooth muscle cells and other cell types [19] and caveolae
components CAV2 (p = 0.07) and PTRF (p < 0.01) were
both decreased in PTSMT. In addition to several blood
vessel-associated factors, lymphatic vessel protein podo-
planin was decreased in PTSMT. Again, in leiomyosarco-
mas, podoplanin-positive vessels are especially found in
tumours with lymph node metastases [20]. In our cohort,
Table 1 Expression profile of angiogenesis-related genes
Gene (abbreviation) Gene name PTSMT (mean) Leiomyomas (mean) Significance
ANGPT1 Angiopoietin 1 0.03 0.51 n.s.
ANGPT2 Angiopoietin 2 0.91 0.31 p = 0.0303
ANGPTL1 Angiopoietin-like 1 0.05 0.05 n.s.
ANGPTL4 Angiopoietin-like 4 0.03 0.05 n.s.
BAI1 Brain-specific angiogenesis inhibitor 1 0.06 0.18 n.s.
CAV2 Caveolin 2 0.84 2.35 n.s.
CDK1 Cyclin-dependent kinase 1 0.01 0.01 n.s.
CXCL1 Chemokine (C-X-C motif) ligand 1 (melanoma
growth stimulating activity, alpha)
4.25 7.55 n.s.
EPHB4 EPH receptor B4 0.06 2.50 p = 0.0025
FGF2 Fibroblast growth factor 2 (basic) 0.01 0.16 p = 0.0121
FGFR1/FLT2 Fibroblast growth factor receptor 1 3.36 21.33 p = 0.0051
GREM1 Gremlin 1, DAN family BMP antagonist 0.14 0.20 n.s.
HGF Hepatocyte growth factor 0.02 0.07 p = 0.0242
HIF1A Hypoxia inducible factor 1, alpha subunit 6.48 13.81 p = 0.0051
IL8 Interleukin 8 0.60 0.03 n.s.
LECT1 Leukocyte cell derived chemotaxin 1 0.11 Not detectable –
MDK Midkine (neurite growth-promoting factor 2) 0.14 1.24 p = 0.0061
MMP2 Matrix metallopeptidase 2 (gelatinase A, 72 kDa
gelatinase, 72 kDa type IV collagenase)
1.19 34.07 p = 0.0025
NOS3 Nitric oxide synthase 3 (endothelial cell) 0.05 0.31 p = 0.0025
NOTCH4 Notch 4 (receptor) 0.28 2.68 p = 0.0025
NOX4 NADPH oxidase 4 0.05 1.32 p = 0.0061
NRP1 Neuropilin 1 0.17 0.82 n.s.
OLR1 Oxidized low density lipoprotein (lectin-like) receptor 1 0.04 0.02 n.s.
PDGFA Platelet-derived growth factor alpha polypeptide 0.36 0.12 p = 0.0480
PDGFRA Platelet-derived growth factor receptor, alpha
polypeptide
1.66 7.31 n.s.
PDPN Podoplanin 0.09 3.36 p = 0.0061
PECAM1/CD31 Platelet/endothelial cell adhesion molecule 20.10 6.76 p = 0.0303
PTGS1 Prostaglandin-endoperoxide synthase 1 (prostaglandin
G/H synthase and cyclooxygenase)
0.41 0.03 p = 0.0061
PTRF Polymerase I and transcript release factor 7.68 56.80 p = 0.0025
S1PR1 Sphingosine-1-phosphate receptor 1 0.15 0.76 p = 0.0172
SERPINF1 Serpin peptidase inhibitor, clade F (alpha-2 antiplasmin,
pigment epithelium derived factor), member 1
0.19 6.45 p = 0.0061
STAB1 Stabilin 1 0.06 0.16 n.s.
TEK TEK tyrosine kinase, endothelial 0.11 1.17 p = 0.0043
TGFBR1 Transforming growth factor, beta receptor 1 0.05 0.38 p = 0.0025
THBS1 Thrombospondin 1 13.56 134.17 p = 0.0025
TIMP2 TIMP metallopeptidase inhibitor 2 9.32 54.78 p = 0.0025
TNFAIP2 Tumor necrosis factor, alpha-induced protein 2 0.08 0.01 n.s.
TYMP Thymidine phosphorylase 0.17 0.08 p = 0.0480
VCAM1 Vascular cell adhesion molecule 1 0.18 0.95 p = 0.0303
VEGFA Vascular endothelial growth factor A 3.38 36.05 p = 0.0025
VEGFC Vascular endothelial growth factor C 0.47 1.66 p = 0.0043
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Table 1 Expression profile of angiogenesis-related genes (Continued)
VEGFD/FIGF C-fos induced growth factor (vascular endothelial
growth factor D)
0.01 0.23 n.s.
VEGFR1/FLT1 Fms-related tyrosine kinase 1 (vascular endothelial
growth factor/vascular permeability factor receptor)
0.15 0.73 p = 0.0061
VEGFR2/KDR Kinase insert domain receptor (a type III receptor
tyrosine kinase)
0.26 3.48 p = 0.0061
VEGFR3/FLT4 Fms-related tyrosine kinase 4 0.08 0.10 n.s.
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general, involvement of lymph nodes is rare in this type of
transplant-associated neoplasm [1]. MMP2, which de-
grades the collagen IV-rich basal membrane as a necessary
requisite for metastasis [21], was reduced in PTSMT,
which indicates no major remodelling of extracellular
matrix during tumour cell and endothelial proliferation.
Compared to leiomyomas, only a few pro-angiogenic
factors such as TYMP, ANGPTL2 and PTGS1 were in-
creased in PTSMT. However, statistical significances were
the result of very low expression levels in leiomyomas ra-
ther than a prominent up-regulation in PTSMT. The
mean relative expression levels of these three factors
was <1, indicating no major role in mediating tumour
angiogenesis.
In PTSMT, three important anti-angiogenetic factors
were decreased: TIMP2, SERPINF1 and THBS1. TIMP2
and SERPINF1 are strong inhibitors of endothelial pro-
liferation [8,22] and THBS1 induces reduced migration
ability of endothelial cells [23]. Furthermore, THBS1 can
inhibit the binding of activating cytokines at receptors of
endothelial cells and can also bind to the thrombospon-
din receptor CD36 which induces endothelial apoptosis
[23]. Other groups found that leiomyomas express
THBS1 more frequently than leiomyosarcomas [24]. In
addition, TIMP2 is also expressed at relatively low levels
in leiomyosarcomas [22].
It has been shown that the transcription factor MYC
leads to expression of the chromosome segment
13q31.3-encoded microRNA 17~92 cluster which in-
cludes the two paralogues miR-19a and miR-19b-1
[25-27]. MicroRNA are non-coding molecules of 20-
25 nucleotides which bind to mRNA and negatively
regulate protein translation [28]. THBS1-mRNA has
a miR-19 binding site and therefore MYC-related
miR-19 expression down-regulates THBS1 [25-27].
PTSMT have an increased MYC expression [1] and
low levels of THBS1 but no up-regulation of the miR
17~92 cluster, including miR-19a (in PTSMT mean
relative expression level 0.02 versus 0.03 in leiomyo-
mas) and miR-19b (mean 1.63 in PTSMT versus 2.23
in leiomyomas) [29]. The microRNA profile in PTSMT is
overall associated with leiomyomatous differentiation of
the tumour cells [29]. Therefore, similar to mesenchymalcells in vitro and in vivo [30], in PTSMT increased MYC
expression is associated with decreased THBS1 expression
but there is no indication for a specific microRNA regula-
tion. Furthermore, while in leiomyosarcomas low expres-
sion of THBS1 and TIMP2 is accompanied by increased
expression of pro-angiogenic factors such as VEGFA,
PTSMT in general did not show such a global pro-
angiogenic expression profile.
As reviewed by Paydas [31], in lymphomas and naso-
pharyngeal carcinomas, tumour cell infection with EBV
is related to increased angiogenesis, in particular because
the viral late membrane protein 1 (LMP1) induces ex-
pression of VEGF and activation of PTGS2, interleukin 8
(IL8), fibroblast growth factor 2 (FGF2) and other pro-
angiogenic factors. Although PTSMT are infected with
EBV, these tumours do not usually express LMP1 pro-
teins [1,2,32] and this could be an explanation why,
despite viral infection, PTSMT show no exaggerated
tumour angiogenesis. It is not known how the EBV+
tumour cells suppress the expression of LMP1 while
expressing other viral proteins and the tumour bio-
logical benefit of this selective lack of LMP1 for the
PTSMT proliferation is also not known.
Although clinical testing has not yet been performed,
on the one hand it is questionable whether patients who
suffer from this type of soft tissue tumour might benefit
from systematic anti-angiogenic drug therapy. On the
other hand, it could be assumed that PTSMT found their
own equilibrium of tumour vascularisation that allows
survival and growth without increasing the expression of
pro-angiogenic factors (e.g. due to aberrant signalling
downstream of pro-angiogenic receptors). This might
principally indicate a limited ability to circumvent therapy
and therefore anti-angiogenic drugs might not necessarily
be ineffective since this would disrupt the equilibrium of
PTSMT vascularisation. Anti-angiogenic drugs could still
be administered to PTSMT patients with no other treat-
ment options available but, in these present analyses, we
could not identify a specific target molecule.
In summary, our analyses of the tumour angiogenesis
in PTSMT revealed no particular target molecule, be-
cause PTSMT are characterised by low levels of major
pro-angiogenic factors and there is no prominent in-
crease in tumour vascularisation.
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Additional file 1: Table S1. Patient cohort. Figure S1. Fluorescence in
situ hybridisation of the MYC gene shows no aneuploidy in endothelial
cells (white arrows) while a subfraction of PTSMT cells had an aneuploidy.
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